AVI BioPharma Announces Partner's Advance in Cardiovascular Program
June 16 2008 - 9:31AM
Marketwired
CORVALLIS, OR today announced that its partner in its
cardiovascular program, Global Therapeutics, the cardiology unit of
Cook Medical, has received CE Mark approval for a new cobalt
chromium bare metal stent. The device, the Global Therapeutics GTX
Coronary Stent System, is also the platform for a breakthrough
drug-eluting stent (DES) technology which utilizes AVI-5126,
developed by AVI. The drug candidate is an improved version of
antisense gene therapy to inhibit the proliferation of c-myc, a
gene known to be involved in the intimal hyperplasia which
underlies the process of vessel restenosis. Cook Medical management
indicates that the clinical trial is expected to begin in the third
quarter of 2008 in Europe.
About Cook Medical:
Cook Medical was one of the first companies to help popularize
interventional medicine, pioneering many of the devices now
commonly used worldwide to perform minimally invasive medical
procedures. Today, the company integrates device design, biopharma,
gene and cell therapy and biotech to enhance patient safety and
improve clinical outcomes in the fields of aortic intervention;
interventional cardiology; critical care medicine;
gastroenterology; radiology, peripheral vascular, bone access and
oncology; surgery and soft tissue repair; urology; and assisted
reproductive technology, gynecology and high-risk obstetrics. Cook
is a past winner of the prestigious Medical Device Manufacturer of
the Year Award from Medical Device & Diagnostic Industry
magazine. For more information, visit www.cookmedical.com.
About AVI BioPharma
AVI BioPharma develops therapeutic products for the treatment of
life-threatening diseases using third-generation NeuGene� antisense
drugs and alternative RNA splicing technology. AVI's alternative
RNA splicing technology is initially being applied to potential
treatments for Duchenne muscular dystrophy. AVI's NeuGene compounds
are also designed to treat post-operative cardiovascular
restenosis. In addition to targeting specific genes in the body,
AVI's antiviral program uses NeuGene antisense compounds to combat
disease by targeting single-stranded RNA viruses, including Marburg
Musoke and Ebola Zaire viruses. More information about AVI is
available at www.avibio.com.
"Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995: The statements that are not historical facts
contained in this release are forward-looking statements that
involve risks and uncertainties, including, but not limited to, the
results of research and development efforts, the results of
preclinical and clinical testing, the effect of regulation by the
FDA and other agencies, the impact of competitive products, product
development, commercialization and technological difficulties, and
other risks detailed in the company's Securities and Exchange
Commission filings.
AVI Press and Investor Contact: Michael Hubbard Email Contact
Director of Corporate Communications (503) 227-0554
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jul 2023 to Jul 2024